TXG
10x Genomics is an American biotechnology company that designs and manufactures gene sequencing technology used in scientific research. It was founded in 2012 by Serge Saxonov, Ben Hindson, and Kevin Ness.
10x Genomics, Inc. (TXG) is rated C+ (2.6/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Momentum (B); its weakest is Value (D). The rating has held at C+ for 5 weeks.
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-15 | D (1.5) | C (2.5) | B- (2.9) | B (3.4) | C+ (2.6) | C+ (2.6) |
| 2026-11-08 | D (1.5) | C (2.5) | B- (2.9) | B (3.4) | C+ (2.6) | C+ (2.6) |
| 2026-11-01 | D (1.5) | C+ (2.8) | B- (2.9) | B (3.4) | C+ (2.7) | C+ (2.7) |
| 2026-10-25 | D (1.5) | C+ (2.8) | B- (2.9) | B (3.4) | C+ (2.6) | C+ (2.6) |
| 2026-10-18 | D (1.5) | C+ (2.8) | B- (2.9) | B (3.4) | C+ (2.6) | C+ (2.6) |